Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: Results of a randomized, double-blinded, placebo-controlled Phase II clinical trial

Bone

Volumn 49, Issue 4, 2011, Pages 845-852

  Fitzpatrick, Lorraine A ^a   Smith, Phillipa L ^b   McBride, Trish A ^a   Fries, Michael A ^a   Hossain, Mohammad ^a   Dabrowski, Christine E ^a   Gordon, David N ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Calcium sensing receptor antagonist; Oral anabolic agent; Radiographic fracture healing; Ronacaleret

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N PROPEPTIDE; RONACALERET; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MASS; BONE RADIOGRAPHY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DYSPEPSIA; FEMALE; FRACTURE HEALING; GRIP STRENGTH; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; PAIN; PARATHYROID HORMONE BLOOD LEVEL; PHASE 2 CLINICAL TRIAL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RHINOPHARYNGITIS; SIDE EFFECT; UPPER ABDOMINAL PAIN;

ADULT; AGED; BIOLOGICAL MARKERS; BONE REMODELING; CALCIUM; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; FRACTURE HEALING; HUMANS; INDANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHENYLPROPIONATES; PLACEBOS; RADIUS FRACTURES; RECEPTORS, CALCIUM-SENSING; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052279587     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.06.017     Document Type: Article

References (22)

1. Melton L.J., Chrischilles E.A., Cooper C., Lane A.W., Riggs B.L. How many women have osteoporosis?. J Bone Miner Res 1992, 7:1005-1010.
2. O'Neill T.W., Cooper C.C., Finn J.D., Lunt M., Purdie D., Reid D.M., et al. Incidence of distal forearm fracture in British men and women. Osteoporos Int 2001, 12:555-558.
3. Greendale G.A., Barrett-Connor E. Outcomes of osteoporotic fractures. Osteoporosis 2001, Volume 1:819-829. Academic Press, San Diego, CA, USA. Second Ed. R. Marcus, D. Feldman, J. Kelsey (Eds.).
4. Barnes G.L., Kakar S., Vora S., Morgan E.F., Gerstenfeld L.C., Einhorn T.A. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg 2008, 90:120-127.
5. Chalidis B., Tzioupis C., Tsiridis E., Giannoudis P.V. Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications. Expert Opin Investig Drugs 2007, 16:441-449.
6. Ellegaard M., Jorgensen N.R., Schwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int 2010, 87:1-13.
7. Aspenberg P., Genant H.K., Johansson T., Nino A.J., See K., Krohn K., et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double blind study of 102 postmenopausal women with distal radius fractures. J Bone Miner Res 2010, 25:404-414.
8. Lindsay R., Nieves J., Henneman E., Shen V., Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993, 77:1535-1539.
9. Brown E.M., MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Endocrinol Rev 2001, 81:239-297.
10. Kumar S., Matheny C.J., Hoffman S.J., Marquis R.W., Schultz M., Liang X., et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010, 46:534-542.
11. Fitzpatrick L.A., Brennan E., Kumar S., Matheny C., Yi B., McLaughlin M., et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J Bone Miner Res 2008, 23:S50.
12. Cook S.D., Ryaby J.P., McCabe J., Frey J.J., Heckman J.D., Kristiansen T.K. Acceleration of tibia and distal radius fracture healing in patients who smoke. Clin Orthop Relat Res 2007, 465:198-207.
13. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., Papapoulos S., Bone H.G., Bilezikian J.P. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. JCEM 2011, jc.2010-2855, Accessed 2 June 2011. 10.1210/jc.2010-2855.
14. Lynch J.A., Grigoryan M., Fierlinger A., Guermazi A., Zaim S., Maclean D.B., et al. Measurement of changes in trabecular bone at fracture sites using X-ray CT and automated image registration and processing. J Orthop Res 2003, 22:362-367.
15. Grigoryan M., Lynch J.A., Fierlinger A.L., Guermazi A., Fan B., Maclean A., et al. Quantitative and qualitative assessment of closed fracture healing using computed tomography and conventional radiography. Acad Radiol 2003, 10:1267-1273.
16. Kalpakcloglu B.B., Morshed S., Engelke K., Genant H.K. Advanced imaging of bone microstructure in bone fragility and fracture repair. J Bone Joint Surg 2008, 90(SUPPL. 1):68-78.
17. Chrischilles E.A., Butler C.D., Davis C.S., Wallace R.B. A model of lifetime osteoporosis impact. Arch Intern Med 1991, 151:2026-2032.
18. Kanis J.A., Oden A., Johnell O., de Laet C., Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001, 12:417-427.
19. Bonner F.J., Sinaki M., Grabois M., Shipp K.M., Lane J.M., Lindsay R., et al. Health professional's guide to rehabilitation of the patient with osteoporosis. Osteoporos Int 2003, 14(SUPPL. 2):S1-S22.
20. Andreassen T.T., Ejersted C., Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999, 14:960-968.
21. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94:335-339. On behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism.
22. Rubin M.R., Bilezikian J.P. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 2003, 32:285-307.